Tissue Regeneration Therapeutics (TRT) is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP family of cell therapy products. TRT has discovered the world's richest source of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC platform technology are founded on the highly enriched source of these important cells compared to other tissue sources

With our partners we create cellular and regenerative strategies that maximize the utility of our platform technology and products - for therapies that address important health care issues of today.

Together, we build very powerful biology.
NEWS!

March 30, 2015 - TRT receives latest notice of Patent Grant from the United States Patent Office.
Read More...

October 17, 2014 - TRT reaches final milestone of a $3.25 Million funding.
Read More...

June 20, 2014 - TRT Cell-Based Bioweapon Defense Technology Presented at the International Society for Stem Cell Research Conference.
Read More...

June 2, 2014 - Tissue Regeneration Therapeutics Inc. (TRT) and Héma-Québec enter a definitive licensing agreement for the first human clinical trial of TXP-1.
Read More...